Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability

Steroids

Volumn 78, Issue 10, 2013, Pages 987-995

  Zhou, Rong ^a   Yao, Xingang ^b   Xu, Xing ^b   Wang, Gaihong ^b   Zhu, Zhiyuan ^b   Chen, Jing ^b   Chen, Lili ^a,b   Shen, Xu ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Diabetes; Pancreatic islet beta cells; Pro inflammatory cytokines; Progesterone receptor; SC51089

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN P53; SC 51089; SC51089; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN PHOSPHORYLATION;

9-CIS RETINOIC ACID; AKT; ANDROGEN RECEPTOR; AR; CORT; CORTICOSTERONE; DEX; DEXAMETHASONE; DHT; DIABETES; DIHYDRO-TESTOSTERONE; DIMETHYL SULFOXIDE; DMEM; DMSO; DULBECCO'S MODIFIED EAGLE'S MEDIUM; ERK; ERΑ; EST; ESTROGEN RECEPTOR Α; ESTRONE; EXTRACELLULAR-SIGNAL-REGULATED KINASE 1/2; FBS; FETAL BOVINE SERUM; GLUCOCORTICOID RECEPTOR; GR; GW; GW501516; IFNΓ; IL-1Β; INTERFERON-Γ; INTERLEUKIN-1Β; LIVER X RECEPTORΑ; LXRΑ; MAPK; MIF; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; MITOGEN-ACTIVATED PROTEIN KINASES; MR; NR; NUCLEAR RECEPTOR; P4; P53; PANCREATIC ISLET BETA CELLS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORΔ/Γ; PIC; PPARΔ/Γ; PR; PR ELEMENTS; PR KNOCKOUT; PR-KO; PRE; PRO-INFLAMMATORY CYTOKINES; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN 53; PROTEIN KINASE B; RA; RETINOID X RECEPTOR Α; ROSI; ROSIGLITAZONE; RXRΑ; SC51089; TNFΑ; TO; TO901317; TRAF2; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR Α;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; HYDRAZINES; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN-SECRETING CELLS; MCF-7 CELLS; MICE; OXAZEPINES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROGESTERONE; TRANSCRIPTION, GENETIC;

EID: 84885001378     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2013.06.005     Document Type: Article

References (30)

1. Branisteanu DD, Mathieu C. Progesterone in gestational diabetes mellitus: guilty or not guilty? Trends Endocrinol Metab 2003;14:54-6.
2. Jarvela IY, Juutinen J, Koskela P, Hartikainen AL, Kulmala P, Knip M, et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 2006;29:607-12.
3. Homko C, Sivan E, Chen X, Reece EA, Boden G. Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab 2001;86:568-73.
4. Picard F, Wanatabe M, Schoonjans K, Lydon J, O'Malley BW, Auwerx J. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta -cell proliferation. Proc Natl Acad Sci U S A 2002;99:15644-8.
5. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 2003;81:455-70.
6. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology 2009;24:325-31.
7. Eizirik DL, Mandrup-Poulsen T. A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001;44:2115-33.
8. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.
9. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
10. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002;277:5209-18.
11. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 2000;20:3102-15.
12. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001;8:269-80.
13. Hsu SP, Lee WS. Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells. Mol Endocrinol 2011;25:421-32.
14. Pavlovic D, Andersen NA, Mandrup-Poulsen T, Eizirik DL. Activation of extracellular signal-regulated kinase (ERK)1/2 contributes to cytokineinduced apoptosis in purified rat pancreatic beta-cells. Eur Cytokine Netw 2000;11:267-74.
15. Reinhard C, Shamoon B, Shyamala V, Williams LT. Tumor necrosis factor alphainduced activation of c-jun N-terminal kinase is mediated by TRAF2. EMBO J 1997;16:1080-92.
16. Hallinan EA, Hagen TJ, Husa RK, Tsymbalov S, Rao SN, VanHoeck JP. N-substituted dibenzoxazepines as analgesic PGE2 antagonists. J Med Chem 1993;36:3293-9.
17. Hallinan EA, Hagen TJ, Tsymbalov S, Husa RK, Lee AC, Stapelfeld A, et al. Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. J Med Chem 1996;39:609-13.
18. Khasar SG, Ho T, Green PG, Levine JD. Comparison of prostaglandin E1- and prostaglandin E2-induced hyperalgesia in the rat. Neuroscience 1994;62:345-50.
19. Malmberg AB, Rafferty MF, Yaksh TL. Antinociceptive effect of spinally delivered prostaglandin E receptor antagonists in the formalin test on the rat. Neurosci Lett 1994;173:193-6.
20. Abe T, Kunz A, Shimamura M, Zhou P, Anrather J, Iadecola C. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab 2009;29:66-72.
21. Matsuo M, Yoshida N, Zaitsu M, Ishii K, Hamasaki Y. Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089. Journal of neuro-oncology. 2004;66:285-92.
22. Wolkowicz PE, Ku DD, Grenett HE, Urthaler F. Occupation of the prostaglandin E2-type 1 receptor increases rat atrial contractility via a Y-27632-sensitive pathway. Prostaglandins Other Lipid Mediat 2002;70:91-105.
23. Lin Z, Zhang Y, Shen H, Hu L, Jiang H, Shen X. Oleanolic acid derivative NPLC441 potently stimulates glucose transport in 3T3-L1 adipocytes via a multi-target mechanism. Biochemical Pharmacol 2008;76:1251-62.
24. Liu Q, Zhang Y, Lin Z, Shen H, Chen L, Hu L, et al. Danshen extract 15,16- dihydrotanshinone I functions as a potential modulator against metabolic syndrome through multi-target pathways. J Steroid Biochem Mol Biol 2010;120:155-63.
25. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, et al. Reexpression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001;61:5771-7.
26. Beaudry JL, Riddell MC. Effects of glucocorticoids and exercise on pancreatic beta-cell function and diabetes development. Diabetes Metab Res Rev 2012;28:560-73.
27. Nadal A, Alonso-Magdalena P, Soriano S, Ropero AB, Quesada I. The role of oestrogens in the adaptation of islets to insulin resistance. J Physiol 2009;587:5031-7.
28. Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 2004;27:645-9.
29. Leonhardt SA, Boonyaratanakornkit V, Edwards DP. Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids 2003;68:761-70.
30. McDonnell DP, Shahbaz MM, Vegeto E, Goldman ME. The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J Steroid Biochem Mol Biol 1994;48:425-32.